ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has shared new real-world evidence on the effectiveness, adherence, and quality-of-life…
Bayer to Present Latest Research on Menopausal Sleep Disturbances at IMS 2024 Bayer is set to showcase its latest research on menopause symptoms, particularly sleep disturbances, at the 19th World Congress of the International Menopause Society (IMS) from October 19-22,…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced new scientific data on its gene therapy, LUMEVOQ®,…
Colossal, a company focused on de-extinction and species preservation, has made significant strides in its efforts to bring back the thylacine, an iconic Australian marsupial that has been extinct since 1936. The company announced breakthroughs across all stages of the…
Grifols Achieves Record Score in 2024 S&P Global Corporate Sustainability Assessment Grifols Secures 70 Points, Demonstrating a Seven-Point Improvement Over Previous Year Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company and manufacturer of plasma-derived medicines, has…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced promising top-line results from a Phase 3 clinical trial assessing the effectiveness of Zepzelca® (lurbinectedin) combined with the PD-L1 inhibitor atezolizumab (Tecentriq®). This combination therapy was evaluated as a maintenance treatment for adults…
Novotech, a full-service international clinical contract research organization (CRO), is proud to announce its recognition as a U.S. Great Place to Work® certified company. This prestigious certification underscores Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment, where…
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor, for HIV prevention among a diverse group of cisgender men…
A team of researchers from City of Hope® and The University of Texas M.D. Anderson Cancer Center has shared promising safety and efficacy results from a Phase 1 trial involving a personalized vaccine for lymphoplasmacytic lymphoma, a rare and slow-growing…
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in cancer immunotherapy. Its potential lies in its ability to stimulate…
PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks a significant milestone for PharmaLegacy as it strengthens its global…
Jackson Egen discovered the significance of fundamental lab research during his graduate studies at UC Berkeley in the 1990s, working under the guidance of esteemed immunologist James Allison. “Jim emphasized that more effective cancer immunotherapies could arise from a deep…